InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.013 -0.002 (-10.71%)+
Announcement
Release
30 Apr 2026 8:39AM
Price at Release
$0.014
Full Release
download
Summary
Algorae Pharmaceuticals Limited reported significant progress in its Quarterly Activities Report for the period ending 31 March 2026. The company, leveraging its AI platform for drug discovery, has enhanced its financial position with cash reserves reaching approximately $5.47 million, largely through net financing inflows. Key developments include a licensing agreement with Cadila Pharmaceuticals and a commercial expansion with Zydus Lifesciences for distribution in Australia and New Zealand. The company continues its R&D efforts with a second validation program at the Peter MacCallum Cancer Centre. Additionally, Algorae bolstered its leadership team with experienced hires to drive commercial success, marking continued efforts in regulatory and market engagement across high-priority therapeutic areas.
Key Points
  • Financial Position: Cash reserves increased to $5.47 million.
  • Commercial Momentum: Executed Licence & Supply Agreement with Cadila Pharmaceuticals.
  • Post-Quarter Commercial Expansion: Agreement with Zydus Lifesciences Ltd.
  • Second Peter Mac Validation Program: Preclinical validation for drug combinations.
  • Commercial Team Strengthened: New appointments in leadership roles.
  • Board Renewal: Appointment and retirement of key board members.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.